Parker, who has a son with a severe peanut allergy, has ended her relationship with Mylan because of the controversial price hikes. She had been involved in an initiative to raise awareness about anaphylaxis with the manufacturer.

“I’m left disappointed, saddened and deeply concerned by Mylan’s actions. I do not condone this decision and I have ended my relationship with Mylan as a direct result of it,” the actress wrote on her Instagram page. “I hope they will seriously consider the outpouring of voices of those millions of people who are dependent on the device, and take swift action to lower the cost to be more affordable by those for whom it is a life-saving necessity.”


Meanwhile, Mylan CEO Heather Bresch told CNBC’s Brian Sullivan in a televised interview that the “system is broken.” She pushed back about the price increases saying it is part of an “outdated, inefficient [health care] system.”

“The patient is paying twice. They’re paying full retail price at the counter, and they’re paying higher premiums on their insurance. It was never intended that a consumer, that the patients would be paying list price, never. The system wasn’t built for that.”

Bresch said in the interview that she had personally reached out to several U.S. senators in hopes of setting up a meeting and had not yet heard back from them. But she also argued that other stakeholders like pharmacy benefit managers, doctors, wholesalers and retailers should also “be at the table” to discuss the rising costs of pharmaceuticals and the role the health care system plays.

“My frustration is that there’s a list price of $608 (for the two-pack EpiPen),” Bresch said adding that there are “four or five hands that the product touches and companies that it goes through before it ever gets to that patient at the counter.”

Back to HCB News

Business Affairs Homepage